| Recruitment status | Preinitiation |
| Unique ID issued by UMIN | UMIN000048714 |
| Receipt No. | R000055439 |
| Scientific Title | Clinical trial for confirming the effect of improving skin transparency by ingesting the test product for 12 weeks |
| Date of disclosure of the study information | 2025/01/01 |
| Last modified on | 2022/08/12 (Ver. 1) |
| Basic information | ||
| Public title | Test for confirming the effect of improving skin transparency by ingesting the test product for 3 months | |
| Acronym | Test for confirming the effect of improving skin transparency by ingesting the test product for 3 months | |
| Scientific Title | Clinical trial for confirming the effect of improving skin transparency by ingesting the test product for 12 weeks | |
| Scientific Title:Acronym | Clinical trial for confirming the effect of improving skin transparency by ingesting the test product for 12 weeks | |
| Region |
|
|
| Condition | ||
| Condition | Healthy person | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To verify ingestion of test food for 12 weeks on skin transparency |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Skin transparency, Skin color |
| Key secondary outcomes | *Secondary index
[1]Observation for skin condition by dermatologists [2]Questionnaire of physical feeling *Safety [1]Doctor's questions *Other index [1]Subject's diary |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Ingestion of test food containing plant mixed extract A and plant mixed extract B (Tablets) for 12 weeks | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Female | |||
| Key inclusion criteria | 1. Those who show their intention to participate in the exam, understand the explanation, and obtain written consent to participate in the exam.
2. Healthy Japanese women aged 35 to 50 who do not violate the exclusion criteria 3. Those who can fill out documents such as consent forms, questionnaires, usage diaries, etc. 4. Those who have felt the effect on the skin with supplements etc. 5. Those who feel a decrease in skin transparency 6. People who tend to get frustrated 7. Those who are dissatisfied with sleep |
|||
| Key exclusion criteria | 1. At the time of obtaining consent, those who regularly use supplements that claim to beautify the skin, diet supplements, collagen supplements, and medicines that may be involved in skin quality (for example, Hythiol C)
2. Those who have significant abnormalities in the skin condition of the test site (face / inside the upper arm) 3. Those with food / drug allergies 4. Those who cannot stop drinking from the day before the measurement date to the end of the measurement 5. Those who smoke on a daily basis 6. Asthma 7. Those who have experience in aesthetic medicine that affects the test site 8. Those who have received a facial treatment and have not passed more than a month 9. Those with chronic skin symptoms such as atopic dermatitis, contact dermatitis, and skin hypersensitivity 10. Those who are currently going to the hospital and using medicines 11. Those who have developed hay fever and are taking medication 12. Those who have a major surgical history in the digestive system, those who have respiratory and heart problems 13. Those who are undergoing hormone replacement therapy for menopause or who have not passed more than 6 months after treatment 14. Those who are participating in a test of ingesting other foods or drugs, or applying cosmetics or drugs, or who have participated in a similar test and have not passed more than 3 months since participating 15. Those who are extremely sunburned or who cannot avoid long hours of outdoor work or sports 16. During lactation or pregnancy,or those who wish to become pregnant during the test period 17. In addition, those who are judged to be ineligible by the investigator and the person responsible for conducting the study |
|||
| Target sample size | 33 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Shiseido Co., Ltd. | ||||||
| Division name | MIRAI Technology Institute | ||||||
| Zip code | 220-0011 | ||||||
| Address | 1-2-11, Takashima, Nishi-ku, Yokohama-shi, Kanagawa 220-0011, Japan | ||||||
| TEL | 045-222-1600 | ||||||
| osamu.ueda@shiseido.com | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Dermalabo Co., Ltd. | ||||||
| Division name | Study Support group | ||||||
| Zip code | 060-0001 | ||||||
| Address | 1-5-2, Chuou-ku, Sapporo-shi, Hokkaido 060-0001, Hokkaido | ||||||
| TEL | 011-205-0781 | ||||||
| Homepage URL | |||||||
| m.matsuzaka@dermalabo.co.jp | |||||||
| Sponsor | |
| Institute | Shiseido Co., Ltd. |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Shiseido Co., Ltd. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Tactics, Hokkaido Revitalization Center, Specified Nonprofit Corporation |
| Address | 2-9 Chuou-ku, Sapporo-shi, Hokkaido, 060-0000, Japan |
| Tel | 011-281-6783 |
| yukiko.iw@gmail.com | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Preinitiation | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB | |||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000055439 |